Cover Image
市場調查報告書

全球何杰金氏淋巴瘤治療市場未來趨勢

Global Hodgkins Lymphoma Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310041
出版日期 內容資訊 英文 79 Pages
訂單完成後即時交付
價格
Back to Top
全球何杰金氏淋巴瘤治療市場未來趨勢 Global Hodgkins Lymphoma Therapeutics Market 2014-2018
出版日期: 2014年08月06日 內容資訊: 英文 79 Pages
簡介

所謂何杰金氏淋巴瘤(HL),定義為在淋巴組織(人體的免疫系的一部分)產生癌症的一種。何杰金氏淋巴瘤的正確的病因不明,不過如果患了使免疫系象衰弱的疾病,病風險便會變高。何杰金氏淋巴瘤的情況,是淋巴系內部的細胞數量戲劇性地增加,擴散至淋巴系內部各處,淋巴球的感染疾病抑制功能損壞,患者容易得感染疾病。最常見的治療方法是化療,接著是放射治療(也有單就化療的情況)。這個疾病不使用外科手術。全球的何杰金氏淋巴瘤相關市場的年複合成長率(CAGR),推算2013∼2018年達到6.84%。

本報告提供全球的何杰金氏淋巴瘤治療的相關市場相關分析、疾病概要和市場結構、市場趨勢(今後5年的預測值)、各地區的詳細趨勢、推動及阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱集

第3章 分析範圍

  • 市場概要
  • 主要的產品與服務
    • 產品簡介

第4章 市場分析技術

  • 市場分析的流程
  • 分析方法

第5章 簡介

第6章 市場環境

  • 市場概況
  • 市場規模與其預測

第7章 世界衛生組織(WHO)的何杰金氏淋巴瘤的分類

第8章 何杰金氏淋巴瘤的分期

第9章 何杰金氏淋巴瘤的化療選擇

  • 波特的五力分析

第10章 各類藥物的市場分析

第11章 各地區的分析

第12章 購買標準

第13章 主要國家的發病率、得病率

  • 美國
  • 英國

第14章 開發中產品現況

第15章 促進市場成長的要素

第16章 推動因素與其影響力

第17章 市場課題

第18章 推動因素、課題的影響力

第19章 市場趨勢

第20章 市場趨勢與其影響

第21章 供應商環境

  • 競爭方案
    • 近幾年的主要趨勢
    • 企業合併、收購(M&A)
  • 市場佔有率分析
  • 其他的著名的供應商

第22章 主要供應商分析

  • Bristol-Myers Squibb Co.
    • 企業概要
    • 產業概要
    • 產品分類
    • 各部門、各地區的銷售額
    • 產業策略
    • 主要資料
    • SWOT分析
  • F. Hoffmann La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

第23章 其他相關分析

圖表一覽

目錄
Product Code: IRTNTR3907

About Hodgkin's Lymphoma

Hodgkin's Lymphoma (HL) is defined as the cancer of the lymph tissue, which is part of our immune system. The exact etiology of HL is unknown. However, the risk of developing the condition is increased if a person suffers from a medical condition that weakens the immune system. In HL, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infection-fighting properties of the lymphocytes are lost, making the person more susceptible to infection. The main treatments used are chemotherapy, followed by radiotherapy or chemotherapy alone. Generally surgery is not used as a treatment for the condition.

TechNavio's analysts forecast the Global Hodgkin's Lymphoma Therapeutics market will grow at a CAGR of 6.84 percent over the period 2013-2018.

Covered in this Report

The Global Hodgkin's Lymphoma Therapeutics market can be divided into eight segments: Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, and Corticosteroids. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of HL that are available in the market.

TechNavio's report, the Global Hodgkin's Lymphoma Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hodgkin's Lymphoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bristol Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • 4SC AG
  • Actinium Pharmaceuticals Inc.
  • Aeterna Zentaris Inc.
  • Affimed Therapeutics AG
  • Hospira Inc.
  • Incyte Corp.
  • Novartis AG
  • Philogen S.p.A.
  • Seattle Genetics Inc.
  • Sigma-Tau Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Teva Pharmaceutical Industries Ltd.

Key Market Driver

  • Improved Diagnostic Techniques.

For a full, detailed list, view our report.

Key Market Challenge

  • High Cost.

For a full, detailed list, view our report.

Key Market Trend

  • Increase in Awareness of HL.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast

07. WHO Classification of Hodgkin's lymphoma

08. Stages of Hodgkin's Lymphoma

09. Chemotherapy Options for Hodgkin's Lymphoma

  • 09.1. Five Forces Analysis

10. Market Segmentation by Drug Class

11. Geographical Segmentation

12. Buying Criteria

13. Rate of Incidence and Prevalence

  • 13.1.1. US
  • 13.1.2. UK

14. Pipeline Snapshot

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
  • 21.3. Other Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Bristol-Myers Squibb Co.
    • 22.1.1. Key Facts
    • 22.1.2. Business Overview
    • 22.1.3. Product Segmentation
    • 22.1.4. Sales by Geography
    • 22.1.5. Business Strategy
    • 22.1.6. Key Information
    • 22.1.7. SWOT Analysis
    • 22.1.8. Strengths
    • 22.1.9. Weaknesses
    • 22.1.10. Opportunities
    • 22.1.11. Threats
  • 22.2. F. Hoffmann La Roche Ltd.
    • 22.2.1. Key Facts
    • 22.2.2. Business Overview
    • 22.2.3. Business Segmentation
    • 22.2.4. Business Segmentation by Revenue 2012 and 2013
    • 22.2.5. Sales by Geography
    • 22.2.6. Business Strategy
    • 22.2.7. Key Information
    • 22.2.8. SWOT Analysis
    • 22.2.9. Strengths
    • 22.2.10. Weaknesses
    • 22.2.11. Opportunities
    • 22.2.12. Threats
  • 22.3. Merck & Co. Inc.
    • 22.3.1. Key Facts
    • 22.3.2. Business Overview
    • 22.3.3. Business Segmentation by Revenue 2013
    • 22.3.4. Business Segmentation by Revenue 2012 and 2013
    • 22.3.5. Sales by Geography
    • 22.3.6. Business Strategy
    • 22.3.7. Key Developments
    • 22.3.8. SWOT Analysis
    • 22.3.9. Strengths
    • 22.3.10. Weaknesses
    • 22.3.11. Opportunities
    • 22.3.12. Threats
  • 22.4. Pfizer Inc.
    • 22.4.1. Key Facts
    • 22.4.2. Business Overview
    • 22.4.3. Business Segmentation by Revenue 2013
    • 22.4.4. Business Segmentation by Revenue 2012 and 2013
    • 22.4.5. Sales by Geography
    • 22.4.6. Business Strategy
    • 22.4.7. Key Developments
    • 22.4.8. SWOT Analysis
    • 22.4.9. Strengths
    • 22.4.10. Weaknesses
    • 22.4.11. Opportunities
    • 22.4.12. Threats

23. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Hodgkin's Lymphoma Therapeutics Market 2013-2018 (US$ million)
  • Exhibit 3: NCI Lymphoma Research Portfolio 2013
  • Exhibit 4: Global Hodgkin's Lymphoma Therapeutics Market Segmentation by Drug Class
  • Exhibit 5: Global Hodgkin's Lymphoma Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 6: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)
  • Exhibit 7: Bristol-Myers Squibb Co.: Sales by Geography 2013
  • Exhibit 8: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 9: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 10: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 11: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 12: Merck & Co. Inc.: Business Segmentation by Revenue 2013
  • Exhibit 13: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 14: Merck & Co. Inc.: Sales by Geography 2013
  • Exhibit 15: Pfizer Inc.: Business Segmentation by Revenue 2013
  • Exhibit 16: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 17: Pfizer Inc.: Sales by Geography 2013
Back to Top